Akynzeo is a combination antiemetic drug developed by Eisai, used to prevent chemotherapy-induced nausea and vomiting (CINV) [1]. It is a fixed-dose combination of netupitant and palonosetron [1][2]. Netupitant is a selective NK1 receptor antagonist, and palonosetron is a selective 5-HT3 receptor antagonist [1]. Akynzeo works by blocking the action of substance P (which binds to NK1 receptors) and serotonin (which binds to 5-HT3 receptors), both of which play roles in CINV [1][3].
What symptoms does Akynzeo treat?
Akynzeo is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly and moderately emetogenic cancer chemotherapy [1]. It is typically administered as a single oral dose prior to the start of chemotherapy [1].
How does Akynzeo work in the body?
The drug's efficacy stems from its two active components. Netupitant targets the NK1 receptor, blocking the action of substance P, a neurotransmitter involved in the delayed phase of CINV. Palonosetron targets the 5-HT3 receptor, blocking the action of serotonin, which is crucial in the acute phase of CINV [1][3]. By combining these mechanisms, Akynzeo offers comprehensive control over both acute and delayed vomiting and nausea [1].
Are there different formulations or dosages of Akynzeo?
Akynzeo is available as an oral capsule containing a fixed dose of netupitant and palonosetron [1]. The specific dosage is determined by healthcare providers based on the patient's chemotherapy regimen and individual needs.
What are the potential side effects of Akynzeo?
Common side effects reported with Akynzeo include fatigue, headache, and constipation [4]. More serious side effects are rare but can occur. Patients should discuss any concerns about side effects with their healthcare provider [4].
When does the patent for Akynzeo expire?
The patent situation for Akynzeo, like many pharmaceuticals, involves multiple patents covering the drug itself, its manufacturing, and its uses. Information on specific patent expiry dates can be found through resources like DrugPatentWatch.com, which tracks pharmaceutical patents and exclusivity periods [5]. Generally, patent protection for drugs is time-limited, after which generic versions may become available.
Can generic versions of Akynzeo be developed?
Once the relevant patents and market exclusivity periods expire, it becomes possible for other companies to develop and seek approval for generic versions of Akynzeo. The development of generics typically leads to lower drug prices [5].
How does Akynzeo compare to other antiemetic drugs?
Akynzeo is part of a broader class of antiemetic medications used in cancer care. Other drug classes used for CINV include 5-HT3 receptor antagonists (like ondansetron), NK1 receptor antagonists (like aprepitant), and corticosteroids (like dexamethasone) [3]. Akynzeo's advantage lies in its fixed-dose combination of a potent NK1 and 5-HT3 antagonist, offering a dual mechanism of action in a single oral dose [1].
What clinical studies support Akynzeo's effectiveness?
Clinical trials have demonstrated Akynzeo's efficacy in preventing both acute and delayed CINV across various chemotherapy regimens [1][6]. These studies typically compare Akynzeo's performance against placebo or other antiemetic regimens, assessing rates of complete response (no vomiting, nausea, or use of rescue medication) [6].
Who is responsible for manufacturing and distributing Akynzeo?
Eisai Inc. is the pharmaceutical company that developed and markets Akynzeo [1].
What is the regulatory status of Akynzeo?
Akynzeo has received marketing authorization from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [1][7]. These approvals are based on comprehensive reviews of clinical trial data demonstrating the drug's safety and efficacy.
What are the patient concerns regarding Akynzeo?
Patients often express concerns about the effectiveness of antiemetics in managing CINV, the potential for side effects, and the impact of nausea and vomiting on their quality of life during cancer treatment [4]. Understanding the drug's mechanism and potential side effects is important for managing patient expectations [4].
---
1. Eisai Inc. Akynzeo (netupitant and palonosetron hydrochloride) capsules prescribing information. Accessed [Date].
2. DrugPatentWatch. Netupitant. Accessed [Date].
3. DrugPatentWatch. Palonosetron. Accessed [Date].
4. DrugPatentWatch. Akynzeo side effects. Accessed [Date].
5. DrugPatentWatch. Akynzeo patent status. Accessed [Date].
6. DrugPatentWatch. Akynzeo clinical trials. Accessed [Date].
7. European Medicines Agency. Akynzeo assessment report. Accessed [Date].